You just read:

Blueprint Medicines Announces New Drug Discovery Program Targeting PRKACA Kinase Fusions for the Treatment of Fibrolamellar Carcinoma at 10th International Liver Cancer Association (ILCA) Annual Conference

News provided by

Blueprint Medicines Corporation

Sep 09, 2016, 08:30 ET